Back to Search Start Over

Decision-Making for Patients With Cerebral Arteriovenous Malformations.

Authors :
Al-Mufti F
Stein A
Damodara N
Joseph-Senatus G
Nuoman R
Nuoaman H
Ammar Adnan Y
Santarelli J
Sahni R
Gandhi CD
Source :
Cardiology in review [Cardiol Rev] 2021 Jan/Feb; Vol. 29 (1), pp. 10-14.
Publication Year :
2021

Abstract

Cerebral arteriovenous malformations (AVMs) are a complex and heterogeneous pathology which require an understanding of the natural history of these lesions, as well as the potential treatment options in order to manage them safely. While treatment is the agreed upon strategy for most ruptured AVMs, the management of unruptured AVMs continues to be debated. More recently, this debate has been fueled by the A Randomized Trial of Unruptured Arteriovenous Malformations (ARUBA) trial which attempts to define the natural history and treatment risk of AVMs. However, the trial has significant shortcomings which limit its broad applicability. In addition, the breadth, efficacy, and safety of potential treatment options continue to improve. This review focuses on defining the natural history of cerebral AVMs, an overview of the ARUBA trial, and the most current treatment paradigm for cerebral AVMs.

Details

Language :
English
ISSN :
1538-4683
Volume :
29
Issue :
1
Database :
MEDLINE
Journal :
Cardiology in review
Publication Type :
Academic Journal
Accession number :
32941265
Full Text :
https://doi.org/10.1097/CRD.0000000000000342